The Guangdong Provincial Drug Administration today (27) issued an announcement on simplifying the registration and approval process of traditional Chinese patent medicines for external use in Hong Kong.
Registered holders of traditional proprietary Chinese medicines for external use that have been used in Hong Kong for more than five years after being approved by the Hong Kong Chinese Medicine Regulatory Commission can submit a registration application to the Guangdong Provincial Drug Administration through simplified procedures. After successful approval, they can go to Dawan District sales.
The Food and Health Bureau of Hong Kong welcomes the arrangement and will actively promote the relevant measures to the proprietary Chinese medicine industry in Hong Kong.
The SAR government has been in close contact with the relevant mainland authorities to follow up and implement a number of measures that are conducive to the development of Chinese medicine in the Greater Bay Area.
Previously, the Mainland and Hong Kong implemented different registration systems for regulating Chinese medicine products. Applicants had to submit respective registration applications for proprietary Chinese medicines in accordance with the registration requirements of the two places and obtain registration before they could sell them there.
The arrangements announced today can facilitate Hong Kong Chinese proprietary Chinese medicine manufacturers to open up the market and create good conditions for Hong Kong proprietary Chinese medicines to "go global" in the long run.
Professor Chen Zhaoshi, Director of the Food and Health Bureau, said: "The SAR government welcomes the formal implementation of the relevant measures and thanks the Central Government and the relevant authorities of Guangdong Province for their continuous support for the development of Chinese medicine in Hong Kong. The SAR Government"
In order to promote the development of Chinese medicine in the Greater Bay Area, the State Administration of Traditional Chinese Medicine issued the "Guangdong-Hong Kong-Macao Greater Bay Area Chinese Medicine Highland Construction Plan (2020-2025)" in September 2020. The main measures related to Hong Kong include: Develop the first Chinese medicine hospital as an opportunity to establish the Greater Bay Area Chinese Medicine Medical Consortium and Chinese Medicine Hospital Cluster; promote Hong Kong Chinese medicine practitioners to practice in public medical institutions in the Mainland; give full play to the advantages of the Hong Kong Chinese Medicine Testing Center and develop into a research center for Chinese medicine testing and quality control International Center; and to simplify the registration and approval process of Hong Kong registered proprietary Chinese medicines for external use in the Greater Bay Area, etc.
At the same time, the State Drug Administration announced the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation and Development Work Plan" in November 2020, and entrusted the Guangdong Provincial Drug Administration to simplify the development of Hong Kong registered proprietary Chinese medicines for external use. The work of the import registration process.